News Releases

SonoMotion initiates First-In-Human clinical trial of its Break Wave™ stone fragmentation system.

SonoMotion secures a $3M SBIR Phase IIB grant from the NIH in support of its Break Wave™ First-In-Human clinical trial. Planned sites include UW, UBC, UCSD, Cleveland Clinic and Chesapeake Urology.

GE Healthcare and SonoMotion sign a second co-development agreement and expand their strategic relationship with an updated OEM agreement.

SonoMotion receives Health Canada ITA approval to initiate its Break Wave™ First-In-Human clinical trial in Canada.

SonoMotion receives FDA IDE approval to initiate its Break Wave™ First-In-Human clinical trial in the United States.

GE Healthcare and SonoMotion establish a strategic partnership and sign a definitive OEM agreement and co-development agreement.

SonoMotion receives a $1.0M SBIR Commercial Readiness Program grant from the NIH for the development of Stone Clear™.

SonoMotion closes on a $4.6M Series-A round led by MedVenture Partners Inc. and with a significant participation by Bioventures Investors.